Zhuhai Trinomab Pharmaceutical Co., Ltd.

A little over two months into 2025 and two Chinese drug makers have reaped the successes of moving their first-in-class pipeline innovations onto the domestic market, while two others have encountered

Chinese venture capital and private equity firms have rushed to pick up stakes in both preclinical- and clinical-stage biotechs for a combined CNY1.5bn ($212m) over the past month, which seemed to buc

While the recent eye-popping $700m series C fundraising by Chinese mRNA vaccine firm ABOGEN INC has dominated the industry’s attention in recent weeks, six more bioventures from China have meanwhile